

10/751,743


INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10761A'	SERIAL NO. 09/038,700
	APPLICANT MORSEY, ET AL.	
	FILING DATE AUGUST 24, 2001	GROUP 1646/644

U.S. PATENT DOCUMENTS												
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
MS		9	3	0	5	8	1	0	4/93	PCT			
		9	8	2	4	8	0	8	6/98	PCT			
MS		9	9	6	7	2	9	3	12/99	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MS			SHAKIB, ET AL.; Identification of Peptide Motifs Recognized by a Human IgG Autoanti-IgE antibody Using a Phase Display Library; Clinical and Experimental Allergy; Vol. 30 No. 7, Pages 1041-1046 (2000) XP001055645.

EXAMINER		DATE CONSIDERED	2/24/05
----------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

2

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10761A	SERIAL NO. 09/938,700
	APPLICANT MORSEY, ET AL.	10/751,743
	FILING DATE AUGUST 24, 2001	GROUP 1644 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MS	4 9 8 0 2 8 6	12/90	Morgan, et al.			
	5 4 3 6 1 4 6	7/95	Shenk, et al.			
	5 6 0 1 8 2 1	2/97	Stanworth, et al.			
MS	5 6 5 3 9 8 0	8/97	Hellman			

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
MS 0 2 6 3 6 5 5	4/88	EP			
9 2 0 6 1 8 0	4/92	PCT			
9 2 2 0 3 1 6	11/92	PCT			
9 2 2 2 6 3 5	12/92	PCT			
9 3 1 4 1 8 8	7/93	PCT			
9 3 2 0 2 2 1	10/93	PCT			
9 4 0 8 5 9 8	4/94	PCT			
9 4 1 2 6 4 9	6/94	PCT			
MS 9 7 3 1 9 4 8	9/97	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1. MS	Burt, et al.; Eur. J. Immunol.; Inhibition of Binding of Rat IgE to rat mast Cells by Synthetic IgE Peptides; Vol. 17:437-440 (1987).
2.	Helm, et al.; Nature; The Mast Cell Binding Site on Human Immunoglobulin E; Vol. 331: 180-183 (1988).
3.	Helm, et al.; Proc. Natl. Acad. Sci.; Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ϵ -chain fragment of 76 amino acids; Vol. 86, p. 9465-9469 (1989).
4.	Vercelli, et al.; Nature; The B-Cell binding site on human immunoglobulin E; Vol. 338:649-651 (1989).
5.	Nio, et al.; FEBS Letter; Inhibition of passive sensitization of human peripheral basophils by synthetic human immunoglobulin E peptide fragments; 319:225-228 (1993).
6.	Nio, et al.; FEBS Letter; Inhibition of passive cutaneous anaphylaxis by synthetic human immunoglobulin E peptide fragments; Vol. 314, No. 3, p 229-231 (1992).
7. MS	Basu, et al.; The J. of Biological Chemistry; Purification and Characterization of Human Recombinant IgE-Fc Fragments that Bind to the Human High Affinity IgE Receptor; Vol. 268, No. 18, p. 13118-13127 (1993).

BEST AVAILABLE COPY

2/25/05



INFORMATION DISCLOSURE CITATION LIST.DOT, 3/99

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10761A	SERIAL NO. 09/938,700
		APPLICANT MORSEY, ET AL.	10/751,743
		FILING DATE AUGUST 24, 2001	GROUP 1644
8.		Vangelista, et al.; The J. of Clinical Investigation; The Immunoglobulin-like modules Cε3 and α2 are the minimal units necessary for human IgE-FcεRI interaction; Vol. 103: p. 1571-1578 (1999).	
9.		Robertson, et al.; Molecular Immunology; IgE Structure-Function relationships Defined by Sequence Directed Antibodies Induced by Synthetic Peptides; Vol. 25, No. 2, p. 103-113 (1988).	
10.		Schwarzbaum, et al.; European J. of Immunology; Mapping of Murine IgE Epitopes Involved in IgE-Fcε Receptor Interactions; 19:1015-1023 (1989).	
11.		Weetall, et al.; The J. of Immunology; Mapping the Site of Interaction between Murine IgE and its High Affinity Receptor with Chimeric Ig ^h ; 145:3849-3854 (1990).	
12.		Presta, et al.; The J. of Biological Chemistry; The Binding Site on Human Immunoglobulin E for Its High Affinity Receptor; 269:26368-26373 (1994).	
13.		Nissim, et al.; The J. of Immunology; Fine Specificity of the IgE Interacton with the Low and High Affinity Fc Receptor ^h ; 150:1365-1374 (1993).	
14.		Del Prado, et al.; Molecular Immunology; Monoclonal Antibodies Against Human IgE, Identification of an Epitope Sharing Properties with the High-Affinity Receptor Binding Site; 28:839-844 (1991).	
15.		Keegan, et al.; Molecular Immunology; Characterization of New Rat Anti-Mouse IgE Monoclonals and their use along with Chimeric IgE to Further Define the Site that Interacts with FcεRII and RεRI; 28:1149-1154 (1991).	
16.		Hook, et al.; Molecular Immunology; Monoclonal Antibodies Defining Epitopes on Human IgE; 28:631-639 (1991).	
17.		Takemoto, et al.; Microbiol. Immunology; Anti-Human IgE Monoclonal Antibodies Recognizing Epitopes Related to the Binding Sites of High and Low Affinity IgE Receptors; 38(1), p 63-71 (1994).	
18.		Baniyashi, et al.; Molecular Immunology; Anti-IgE Monoclonal Antibodies Directed at the Fcε Receptor Binding Site; 25:705-711 (1988).	
19.		Chang, T.W.; Nature; The Pharmacological Basis of Anti-IgE Therapy; 157-162 (2000).	
20.		Presta, et al.; The J. of Immunology; Humanization of an Antibody Directed Against IgE; 151:2623-2632 (1993).	
21.		Stadler, et al.; Int. Arch Allergy Immunol.; Biological Activities of Anti-IgE Antibodies; 102:121-126 (1993).	
22.		Rudolf, et al.; J. of Immunology; Epitope-Specific Antibody Response to IgE by Mimotope Immunization ^h ; 160:3515-3321 (1998).	
23.		Xiu-min Li, et al.; J. Allergy Clin. Immunology; A Murine Model of IgE-mediated cow's milk hypersensitivity; 103:206-214 (1999).	
24.		Xui-Min Li, et al.; J. Allergy Clin. Immunology; Murine Model of Atopic Dermatitis Associated with Food Hypersensitivity; 107:693-702 (2001).	
25.		Ernel, et al.; Laboratory Animal Science; The Atopic Dog: A Model for Food Allergy; Vol. 47, No. 1, p. 40-48 (1997).	
26.		McDermott, et al.; Molecular Immunology; Identification, cloning, and characterization of a major cat flea salivary allergen (Cte f 1) 37:361-375 (2000).	
27.		Underwood, et al.; Immunology; IgE Production, Antigen-induced airway inflammation and Airway Hyperreactivity in the Brown Norway rat: the Effects of Ricin; 85:256-261 (1995).	
28.		Underwood, et al.; Int. Arch Allergy Immunology; Ricin Increases IgE Levels and Airway Inflammation but Not Hyperresponsiveness in the Rat; 107:119-121 (1995).	
29.		Diaz-Sanchez, et al.; Immunology; Generation of a long-lived IgE Response in High and Low Responder Strains of rat by co-administration of Ricin and Antigen; Immunology; 72:297-303 (1991).	

BEST AVAILABLE COPY

2/25/05

4



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10761A	SERIAL NO. 09/038,700
		APPLICANT MORSEY, ET AL.	10/751,743
		FILING DATE AUGUST 24, 2001	GROUP 1644
30.		Noble, et al.; Immunology; Elimination of IgE Regulatory Rat CD8 ⁺ T Cells in Vivo Increases the Co-ordinate Expression of Th2 cytokines IL-4, IL-5 and IL-10; 80:326-329 (1993).	
31.		Diaz-Sanchez, et al.; Immunology; Ricin Enhances IgE responses by Inhibiting a Subpopulation of Early-Activated IgE Regulatory CD8 ⁺ T Cells; 78:226-236 (1993).	
32.		Karlin, et al.; Proc. Natl. Acad. Sci.; Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes; Vol. 87, p. 2264-2268 (1990).	
33.		Karlin, et al.; Proc. Natl. Acad. Sci.; Applications and Statistics for Multiple High-scoring Segments in Molecular Sequences; Vol. 90, p. 5873-5877 (1993).	
34.		Pearson, et al.; Proc. Natl. Acad. Sci.; Improved Tools for Biological Sequence Comparison; Vol. 85, p. 24444-2448 (1988).	
35.		Benoist, et al.; Nature; In Vivo Sequence Requirements of the SV40 Early Promoter Region; 290:304-310 (1981).	
36.		Yamamoto, et al.; Cell; Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus; Vol. 22, p. 787-797 (1980).	
37.		Wagner, et al.; Proc. Natl. Acad. Sci.; Nucleotide Sequence of the Thymidine Kinase Gene of Herpes Simplex Virus Type 1; Vol. 78, No. 3, p. 1441-1445 (1981).	
38.		Brinster, et al.; Nature; Regulation of Metallothionein-thymidine Kinase Fusion plasmids injected into Mouse Eggs; 296:39-42 (1982).	
39.		Villa-Komaroff, et al.; Proc. Natl. Acad. Sci.; A Bacterial Clone Synthesizing Proinsulin; 75:3727-3731 (1978).	
40.		DeBoer, et al.; Proc. Natl. Acad. Sci.; The tac promoter: A functional hybrid derived from the trp and lac promoters; Vol. 80, p. 21-25 (1983).	
41.		Gilbert, et al.; Scientific American; Useful Proteins from Recombinant Bacteria; 242:74-94 (1980).	
42.		Torelli, et al.; Comput Appl. Biosci.; Advance and Adam: Two algorithms for the analysis of global similarity between homologous informational sequences; Vol. 10, No. 1, p. 3-5 (1994).	
43.		Herrera-Estrella, et al.; Nucl. Acids Res.; Expression of chimaeric genes transferred into plant cells using a Ti-plasmid-derived vector; 303:209-213. (1983).	
44.		Gardner, et al.; Nucl. Acids Res.; Abstract; Vol. 9, No. 12, p. 2871-2888 (1981).	
45.		Herrera-Estrella, et al.; Nature; 310:115-120 (1984).	
46.		Swift, et al.; Cell; Tissue-Specific Expression of the Rat Pancreatic Elastase I Gene in Transgenic Mice; 38:639-646 (1984).	
47.		Ornitz, et al.; Cold Spring Harbor Symp. Quant. Biol.; Elastase I Promoter Directs Expression of Human Growth Hormone and SV40 T Antigen Genes to Pancreatic Acinar Cells in Transgenic Mice; 50:399-409 (1986).	
48.		MacDonald, R.J.; Hepatology; Expression of the Pancreatic Elastase I Gene in Transgenic Mice; 7:425-515 (1987).	
49.		Hanahan, D.; Nature; Heritable formation of pancreatic β -cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes; 315:115-122 (1985).	
50.		Grosschedl, et al.; Cell; Introduction of a μ Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody; 38:647-658 (1984).	
51.		Adams, et al.; Nature; The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice; 318:533-538 (1985).	


BEST AVAILABLE COPY

2/25/05

5

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10761A	SERIAL NO. 09/038,700
		APPLICANT MORSEY, ET AL.	10/751,743
		FILING DATE AUGUST 24, 2001	GROUP 1644

52.		Alexander, et al.; Molecular and Cellular Biology; Expression of the c-myc Oncogene under control of an immunoglobulin enhancer in Eμ-myc Transgenic Mice; Vol. 7, No. 4, p. 1436-1444 (1987).
53.		Pattengale, et al.; Cell; Consequences of Widespread Deregulation of the c-myc Gene in Transgenic Mice: Multiple Neoplasms and Normal Development; Vol. 45, p. 485-495 (1986).
54.		Leder, et al.; Cell; Consequences of Widespread Deregulation of the c-myc gene in transgenic mice: Multiple Neoplasms and Normal Development; 45:485-495 (1986).
55.		Pinkert, et al.; Genes and Development; An albumin enhancer located 10-kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice; 1:268-276 (1987).
56.		Krumlauf, et al.; Molecular and Cellular Biology; Developmental Regulation of α-Fetoprotein Genes in Transgenic Mice; Vol. 5, No. 7, p. 1639-1648 (1985).
57.		Hammer, et al.; Science; Diversity of Alpha-Fetoprotein Gene Expression in Mice Is Generated by a Combination of Separate Enhancer Elements; 235:53-58 (1987).
58.		Kelsey, et al.; Genes & Development; Species- and tissue-specific expression of human α ₁ -antitrypsin in transgenic mice; 1:161-171 (1987).
59.		Magram, et al.; Nature; Developmental regulation of a cloned adult β-globin gene in transgenic mice; 315:338-340 (1985).
60.		Kollias, et al.; Cell; Regulated Expression of Human γ-, β-, and Hybrid γβ-Globin Genes in Transgenic Mice: Manipulation of the Developmental Expression Patterns; Vol. 46, 89-94 (1986).
61.		Readhead, et al.; Cell; Expression of a Myelin Basic Protein Gene in Transgenic Shiverer Mice: Correction of the Dysmyelinating Phenotype; Vol. 48, 703-712 (1987).
62.		Shanl, M.; Nature; Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice; Vol. 314:283-286 (1985).
63.		Reecy, et al.; Animal Biotechnology; Multiple Regions of the Porcine α-Skeletal Actin Gene Modulate Muscle-specific Expression in Cell Culture and Directly Injected Skeletal Muscle; 9(2), p. 101-120 (1998).
64.		Mason, et al.; Science; The Hypogonadal Mouse: Reproductive Functions Restored by Gene Therapy; Vol. 234:1273-1378 (1986).
65.		Wigler, et al.; Cell; Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells; Vol. 11 p. 223-232 (1977).
66.		Szybalska, et al.; Proc. Natl. Acad. Sci.; Genetic of Human Cell Lines, IV.; 48:2026-2034 (1962).
67.		Lowy, et al.; Cell; Isolation of Transforming DNA: Cloning the Hamster apt Gene; Vol. 22, p. 817-823 (1980).
68.		Wigler, et al.; Proc. Natl. Acad. Sci.; Transformation of mammalian cells with an amplifiable dominant-acting gene; Vol. 77, No. 6, p. 3567-3570 (1980).
69.		O'Hare, et al.; Proc. Natl. Acad. Sci.; Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase; 78:1527 (1981).
70.		Mulligan, et al.; Proc. Natl. Acad. Sci.; Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase; Vol. 78, No. 4, p. 2072-2076 (1981).
71.		Colbere-Garapin, et al.; J. Mol. Biol.; A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells; 150:1-14 (1981).
72.		Santerre, et al.; Gene; Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells; 30:147-156 (1984).
73.		Goldspiel, et al.; Clinical Pharmacy; Clinical Frontiers; Vol. 12, p. 488-505 (1993).



BEST AVAILABLE COPY

2/25/05

6

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10761A	SERIAL NO. 99/938,700
		APPLICANT MORSEY, ET AL.	10/751,743
		FILING DATE AUGUST 24, 2001	GROUP 1644

74.	Wu, et al.; Biotherapy; Delivery systems for gene therapy; 3:87-95 (1991).
75.	Tolstoshev; Ann. Rev. Pharmacol. Toxicol.; Gene Therapy, Concepts, Current Trials and Future Directions; 32:573-596 (1993).
76.	Mulligan, R.; Science; The Basic Science of Gene Therapy; 260:926-932 (1993).
77.	Morgan and Anderson, et al.; Ann. Rev. Biochem.; Human Gene Therapy; 62:191-217 (1993).
78.	Robinson, C.; Tibtech; Gene Therapy - proceeding from laboratory to clinic; 11(5):155-215 (1993).
79.	Koller, et al.; Proc. Natl. Acad. Sci.; Inactivating the β_2 -microglobulin locus in mouse embryonic stem cells by homologous recombination; Vol. 86, p. 8932-8935 (1989).
80.	Koller, et al.; Proc. Natl. Acad. Sci.; Inactivating the β_2 -microglobulin locus in mouse embryonic stem cells by homologous recombination; Vol. 86, p. 8932-8935 (1989).
81.	Zijlstra, et al.; Nature; Germ-line transmission of a disrupted β_2 -microglobulin gene produced by homologous recombination in embryonic stem cells; 342:435-438 (1989).
82.	Wu, et al.; J. Biol. Chem.; Recetor-mediated in Vetro Gene Transformation by a Soluble DNA Carrier System; Vol. 262, No. 10, p. 4429-4432 (1987).
83.	Miller, et al.; Meth. Enzymol.; Use of Retroviral Vectors for Gene Transfer and Expression; 217:581-599 (1993).
84.	Clowes, et al.; J. Clin. Invest; Long-Term Biological Response of Injured Rat Carotid Artery Seeded with Smooth Muscle Cells Expressing Retrovirally Introduced Human Genes; 93:644-651 (1994).
85.	Kiem, et al.; Blood; Retrovirus-Mediated Gene Transduction Into Canine Peripheral Blood Repopulating Cells; 83:1467-1473 (1994).
86.	Salmons, et al.; Human Gene Therapy; Targeting of Retroviral Vectors for Gene Therapy; 4:129-141 (1993).
87.	Grossman, et al.; Current Opinion in Genetics and Devel.; Retroviruses: delivery vehicle to the liver; 3:110-114 (1993).
88.	Bout, et al.; Human Gene Therapy; Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium; 5:3-10 (1994).
89.	Rosenfeld, et al.; Science; Adenovirus-Mediated Transfer of a Recombinant α -1-Antitrypsin Gene to the Lung Epithelium in Vivo; 252:431-434 (1991).
90.	Rosenfeld, et al.; Cell; In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium; 68:143-155 (1992).
91.	Mastrangeli, et al.; J. Clin. Invest.; Diversity of Airway Epithelial Cell Targets for the Vivo Recombinant Adenovirus-mediated Gene Transfer; 91:225-234 (1993).
92.	Wang, et al.; Gene Therapy; A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-regio deletions; 2:775-783 (1995).
93.	Walsh, et al.; Proc. Soc. Exp. Biol. Med.; Gene Therapy for Human Hemoglobinopathies; 204:289-300. (1993).
94.	Loeffler, et al; Methods in Enzymology; 217:599-618 (1993).
95.	Cotten, et al.; Methods in Enzymology; Receptor-Mediated Transport of DNA into Eukaryotic Cells; Vol. 217, p. 618-644 (1993).
96.	Cline, M.; Pharmac. Ther.; Perspectives for Gene Therapy; 29:69-92 (1986).
97.	Stemple, et al.; Cell; Isolation of a Stem Cell for Neurons and Glia from the Mammalian Neural Crest; 71:973-985 (1992).


BEST AVAILABLE COPY

2/25/05

7

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10761A	SERIAL NO. 09/938,700
		APPLICANT MORSEY, ET AL. 10/751,743	
		FILING DATE AUGUST 24, 2001	GROUP 1644

98.	<input checked="" type="checkbox"/>	Rheinwald, J.; Methods in Cell Biology; Serial Cultivation of Normal Human Epidermal Keratinocytes; 21a:229-255(1980).
99.	<input type="checkbox"/>	Pittelkow, et al.; Mayo Clinic Proc.; New Techniques for the In Vitro Culture of Human Skin Keratinocytes and Perspectives on Their Use for Grafting of Patients with Extensive Burns; 61:771-777 (1986).
100.	<input type="checkbox"/>	Langer, R.; Science; New Methods of Drug Delivery; 249:1527-1533 (1990).
101.	<input type="checkbox"/>	Treat, et al.; Liposomes in the Therapy of Infectious Diseases and Cancer; Liposome Encapsulated Doxorubicin Preliminary Results of Phase I and Phase II Trials; pp. 353-365 (1989).
102.	<input type="checkbox"/>	Sefton, M.; CRC Crit Ref. Biomed. Eng.; Implantable Pumps; 14:201-240 (1987).
103.	<input type="checkbox"/>	Buchwald, et al.; Surgery; Long-Term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis; 88:507-116 (1980).
104.	<input type="checkbox"/>	Saudek, et al.; New Engl. J. Med.; A preliminary trial of the programmable implantable medication system for insulin delivery; 321:574-579 (1989).
105.	<input type="checkbox"/>	Levy, et al.; Science; Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate; 228:190-192 (1985).
106.	<input type="checkbox"/>	During, et al.; Am. Neurological Assoc.; Controlled Release of Dopamine from a polymeric brain implant: In vivo characterization; 25:351-356 (1989).
107.	<input type="checkbox"/>	Howard, et al.; J. Neurosurg; Intracerebral drug delivery in rats with lesion-induced memory deficits; 71:105-112 (1989).
108.	<input type="checkbox"/>	Goodson; Medical Appins. of Controlled Release supra Vol. II p. 115-138 (1984).
109.	<input type="checkbox"/>	Joliet, et al.; Proc. Natl. Acad. Sci.; Antennapedia homeobox peptide regulates neural morphogenesis; 88:1864-1868 (1991).
110.	<input checked="" type="checkbox"/>	Langer, et al.; JMS - Rev. Macromol. Chem. Phys.; Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review; 23:61-126 (1983).

EXAMINER		DATE CONSIDERED	2/25/05
----------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

BEST AVAILABLE COPY

INFORMATION DISCLOSURE CITATION LIST NOT POSTED